Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Differential expression of the semaphorin 3A pathway in prostatic cancer.

Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G.

Histopathology. 2009 Oct;55(4):392-8. doi: 10.1111/j.1365-2559.2009.03406.x.

PMID:
19817889
2.

The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.

Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh-Xuan AT.

BJU Int. 2007 May;99(5):1150-3.

3.

Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.

Peyromaure M, Badoual C, Camparo P, Grabar S, Goulvestre C, Fulla Y, Vieillefond A, Mao K, Dinh-Xuan AT.

Oncol Rep. 2007 Jul;18(1):145-9.

PMID:
17549360
4.

Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.

Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM.

Cancer Res. 2002 Oct 15;62(20):5974-9.

5.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66.

PMID:
16806661
6.
7.

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.

Olsson CA, de Vries GM, Raffo AJ, Benson MC, O'Toole K, Cao Y, Buttyan RE, Katz AE.

J Urol. 1996 May;155(5):1557-62.

PMID:
8627821
9.

Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis.

Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G.

J Biol Chem. 2007 Sep 7;282(36):26294-305.

10.
11.
12.

VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.

Talagas M, Uguen A, Garlantezec R, Fournier G, Doucet L, Gobin E, Marcorelles P, Volant A, DE Braekeleer M.

Anticancer Res. 2013 May;33(5):2065-75.

PMID:
23645757
13.

Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer.

Müller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, Büchler P, Giese T, Büchler MW, Offermanns S, Friess H.

Int J Cancer. 2007 Dec 1;121(11):2421-33.

14.

Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.

Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G.

Prostate. 2000 Sep 15;45(1):72-9.

PMID:
10960845
15.

Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.

Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5377-84.

16.
17.

Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.

Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I.

Pathol Res Pract. 2006;202(2):93-8.

PMID:
16413692
19.

Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression.

Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil Diez de Medina S, Moutereau S, Maillé P, Soyeux P, Abbou C, Salomon L, Vacherot F, de La Taille A, Loric S, Allory Y.

J Pathol. 2008 Dec;216(4):460-70. doi: 10.1002/path.2427.

PMID:
18825689
20.
Items per page

Supplemental Content

Support Center